董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jonathan MacQuitty | 男 | Chair of the Board | 68 | 18.31万美元 | 未持股 | 2021-03-19 |
| John West | 男 | President, Chief Executive Officer, and Director | 64 | 338.31万美元 | 未持股 | 2021-03-19 |
| Alan Colowick | 男 | Director | 58 | 13.61万美元 | 未持股 | 2021-03-19 |
| Kenneth Ludlum | 男 | Director | 67 | 15.26万美元 | 未持股 | 2021-03-19 |
| Woodrow A. Myers, Jr. | 男 | Director | 67 | 未披露 | 未持股 | 2021-03-19 |
| Karin Eastham | 女 | Director | 71 | 14.61万美元 | 未持股 | 2021-03-19 |
| A. Blaine Bowman | 男 | Director | 74 | 14.11万美元 | 未持股 | 2021-03-19 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| John West | 男 | President, Chief Executive Officer, and Director | 64 | 338.31万美元 | 未持股 | 2021-03-19 |
| Aaron Tachibana | 男 | Chief Financial Officer | 60 | 151.45万美元 | 未持股 | 2021-03-19 |
| Richard Chen | 男 | Chief Scientific Officer | 50 | 143.65万美元 | 未持股 | 2021-03-19 |
董事简历
中英对照 | 中文 | 英文- Jonathan MacQuitty
-
Jonathan MacQuitty博士自2011年6月起担任董事会主席。自2018年7月以来，他担任D2G Oncology, Inc.(肿瘤生物技术公司)的董事会成员和首席执行官。自2016年4月起，他担任Lightspeed Venture Partners(早期风险投资公司)的风险合伙人。2015年5月至2017年4月，他担任47,Inc.(免疫肿瘤公司)的首席执行官。1999年5月至2014年12月，他担任Abingworth Management Inc(跨大西洋生物投资公司)的多种职务，包括合伙人。MacQuitty博士持有牛津大学(Oxford University)化学学士和硕士学位，苏塞克斯大学(University of Sussex)化学博士学位，斯坦福大学商学院(Stanford Graduate School of Business)工商管理硕士学位。
Jonathan MacQuitty, Ph.D. Personalis, Inc. Chair of the Board, has served on our Board of Directors since June 2011. Since July 2018 Dr. MacQuitty has served on the board of directors and as Chief Executive Officer of D2G Oncology, Inc., an oncology biotechnology company. Since April 2016 Dr. MacQuitty has served as a Venture Partner at Lightspeed Venture Partners, an early-stage venture capital firm. From May 2015 to April 2017 Dr. MacQuitty served as Chief Executive Officer of Forty Seven, Inc., an immuno-oncology company. From May 1999 to December 2014 Dr. MacQuitty served in various roles, including Partner, at Abingworth Management Inc., a trans-Atlantic bio-investment firm. Dr. MacQuitty holds a B.A. and M.A. in Chemistry from Oxford University, a Ph.D. in Chemistry from the University of Sussex, and an M.B.A. from the Stanford Graduate School of Business. - Jonathan MacQuitty博士自2011年6月起担任董事会主席。自2018年7月以来，他担任D2G Oncology, Inc.(肿瘤生物技术公司)的董事会成员和首席执行官。自2016年4月起，他担任Lightspeed Venture Partners(早期风险投资公司)的风险合伙人。2015年5月至2017年4月，他担任47,Inc.(免疫肿瘤公司)的首席执行官。1999年5月至2014年12月，他担任Abingworth Management Inc(跨大西洋生物投资公司)的多种职务，包括合伙人。MacQuitty博士持有牛津大学(Oxford University)化学学士和硕士学位，苏塞克斯大学(University of Sussex)化学博士学位，斯坦福大学商学院(Stanford Graduate School of Business)工商管理硕士学位。
- Jonathan MacQuitty, Ph.D. Personalis, Inc. Chair of the Board, has served on our Board of Directors since June 2011. Since July 2018 Dr. MacQuitty has served on the board of directors and as Chief Executive Officer of D2G Oncology, Inc., an oncology biotechnology company. Since April 2016 Dr. MacQuitty has served as a Venture Partner at Lightspeed Venture Partners, an early-stage venture capital firm. From May 2015 to April 2017 Dr. MacQuitty served as Chief Executive Officer of Forty Seven, Inc., an immuno-oncology company. From May 1999 to December 2014 Dr. MacQuitty served in various roles, including Partner, at Abingworth Management Inc., a trans-Atlantic bio-investment firm. Dr. MacQuitty holds a B.A. and M.A. in Chemistry from Oxford University, a Ph.D. in Chemistry from the University of Sussex, and an M.B.A. from the Stanford Graduate School of Business.
- John West
-
John West，他是Personalis, Inc.的创始人之一，自2011年8月起担任Personalis, Inc.的首席执行官和董事。从2009年5月到2011年7月，他担任ViaCyte, Inc.(再生医学公司)的首席执行官。从2004年8月到2008年1月，他担任各种职务，包括从2004年8月到2005年3月担任Solexa, Ltd (DNA测序公司，后来成为Solexa, Inc.)的首席执行官，从2005年3月到2007年1月担任Solexa, Inc.的首席执行官。2007年1月至2008年1月担任Illumina公司(生物技术公司)的DNA测序高级副总裁，此前Solexa公司被Illumina公司收购。West先生的早期职业生涯包括与DNA测序自动化相关的职位。他持有麻省理工学院(Massachusetts Institute of Technology)的核工程学士学位和机械工程硕士学位，以及宾夕法尼亚大学(University of Pennsylvania)沃顿商学院(Wharton School)的工商管理硕士学位。
John West is one of Personalis, Inc. founders and has served as Chief Executive Officer and as a member of Personalis, Inc. of Directors since August 2011. From May 2009 to July 2011 Mr. West served as Chief Executive Officer of ViaCyte, Inc., a regenerative medicine company. From August 2004 to January 2008 Mr. West served in various roles, including Chief Executive Officer from August 2004 to March 2005 at Solexa, Ltd., a DNA sequencing company, which became Solexa, Inc., Chief Executive Officer from March 2005 to January 2007 at Solexa, Inc., and Senior Vice President of DNA Sequencing from January 2007 to January 2008 at Illumina, Inc., a biotechnology company, after the sale of Solexa, Inc. to Illumina, Inc. Mr. West's earlier career included positions related to DNA sequencing automation. Mr. West holds a B.S. in Nuclear Engineering and an M.S. in Mechanical Engineering from Massachusetts Institute of Technology and an M.B.A. from the Wharton School at the University of Pennsylvania. - John West，他是Personalis, Inc.的创始人之一，自2011年8月起担任Personalis, Inc.的首席执行官和董事。从2009年5月到2011年7月，他担任ViaCyte, Inc.(再生医学公司)的首席执行官。从2004年8月到2008年1月，他担任各种职务，包括从2004年8月到2005年3月担任Solexa, Ltd (DNA测序公司，后来成为Solexa, Inc.)的首席执行官，从2005年3月到2007年1月担任Solexa, Inc.的首席执行官。2007年1月至2008年1月担任Illumina公司(生物技术公司)的DNA测序高级副总裁，此前Solexa公司被Illumina公司收购。West先生的早期职业生涯包括与DNA测序自动化相关的职位。他持有麻省理工学院(Massachusetts Institute of Technology)的核工程学士学位和机械工程硕士学位，以及宾夕法尼亚大学(University of Pennsylvania)沃顿商学院(Wharton School)的工商管理硕士学位。
- John West is one of Personalis, Inc. founders and has served as Chief Executive Officer and as a member of Personalis, Inc. of Directors since August 2011. From May 2009 to July 2011 Mr. West served as Chief Executive Officer of ViaCyte, Inc., a regenerative medicine company. From August 2004 to January 2008 Mr. West served in various roles, including Chief Executive Officer from August 2004 to March 2005 at Solexa, Ltd., a DNA sequencing company, which became Solexa, Inc., Chief Executive Officer from March 2005 to January 2007 at Solexa, Inc., and Senior Vice President of DNA Sequencing from January 2007 to January 2008 at Illumina, Inc., a biotechnology company, after the sale of Solexa, Inc. to Illumina, Inc. Mr. West's earlier career included positions related to DNA sequencing automation. Mr. West holds a B.S. in Nuclear Engineering and an M.S. in Mechanical Engineering from Massachusetts Institute of Technology and an M.B.A. from the Wharton School at the University of Pennsylvania.
- Alan Colowick
-
Alan Colowick，医学博士，自2019年5月起担任Personalis, Inc.的董事。自2021年3月起，他担任Harpoon Therapeutics, Inc.(上市的临床阶段免疫治疗公司)的董事会成员。从2017年5月到2021年1月，他担任Sofinnova Investment, Inc.(临床阶段生命科学风险投资公司)的合伙人。从2010年2月到2017年4月，他在Celgene Corporation(制药公司)担任多个职位，包括执行副总裁。从2008年2月到2010年1月，他担任Gloucester Pharmaceuticals Inc.(一家早期癌症制药公司)的首席执行官，直到2010年1月被Celgene Corporation收购。从2006年10月到2008年2月，他担任Geron Corporation(早期制药公司)肿瘤学总裁。在职业生涯早期，他曾担任Amgen Inc.(生物制药公司)的各种职务。他曾担任Principia Biopharma, Inc.(上市的生物制药公司)的董事会成员(从2017年2月到2020年9月);Achaogen, Inc.(上市的生物制药公司)的董事会成员(从2015年8月到2017年8月);Dimension Therapeutics, Inc.(上市的生物制药公司)的董事会成员(从2015年8月到2017年11月)。他持有the University of Colorado的分子生物学学士学位，Stanford University School of Medicine的医学博士学位，以及the Harvard School of Public Health的公共卫生硕士学位。
Alan Colowick, M.D. Dr. Colowick has served on Personalis, Inc. of Directors since May 2019. Dr. Colowick has served on the board of directors of Harpoon Therapeutics, Inc., a publicly traded clinical stage immunotherapy company, since March 2021. From May 2017 to January 2021 Dr. Colowick served as a Partner at Sofinnova Investment, Inc., a clinical stage life sciences venture capital firm. From February 2010 to April 2017 Dr. Colowick held various positions, including Executive Vice President, at Celgene Corporation, a pharmaceutical company. From February 2008 to January 2010 Dr. Colowick served as the Chief Executive Officer of Gloucester Pharmaceuticals Inc., an early stage cancer pharmaceutical company, until its acquisition by Celgene Corporation in January 2010. From October 2006 to February 2008 Dr. Colowick served as President, Oncology at Geron Corporation, an early stage pharmaceutical company. Earlier in his career, Dr. Colowick served in various capacities at Amgen Inc., a biopharmaceutical company. Dr. Colowick previously served on the boards of directors of Principia Biopharma, Inc., a publicly traded biopharmaceutical company, from February 2017 to September 2020 Achaogen, Inc., a publicly traded biopharmaceutical company, from August 2015 to August 2017 and Dimension Therapeutics, Inc., a publicly traded biopharmaceutical company, from August 2015 to November 2017. Dr. Colowick holds a B.S. in Molecular Biology from the University of Colorado, an M.D. from Stanford University School of Medicine, and an M.P.H. from the Harvard School of Public Health. - Alan Colowick，医学博士，自2019年5月起担任Personalis, Inc.的董事。自2021年3月起，他担任Harpoon Therapeutics, Inc.(上市的临床阶段免疫治疗公司)的董事会成员。从2017年5月到2021年1月，他担任Sofinnova Investment, Inc.(临床阶段生命科学风险投资公司)的合伙人。从2010年2月到2017年4月，他在Celgene Corporation(制药公司)担任多个职位，包括执行副总裁。从2008年2月到2010年1月，他担任Gloucester Pharmaceuticals Inc.(一家早期癌症制药公司)的首席执行官，直到2010年1月被Celgene Corporation收购。从2006年10月到2008年2月，他担任Geron Corporation(早期制药公司)肿瘤学总裁。在职业生涯早期，他曾担任Amgen Inc.(生物制药公司)的各种职务。他曾担任Principia Biopharma, Inc.(上市的生物制药公司)的董事会成员(从2017年2月到2020年9月);Achaogen, Inc.(上市的生物制药公司)的董事会成员(从2015年8月到2017年8月);Dimension Therapeutics, Inc.(上市的生物制药公司)的董事会成员(从2015年8月到2017年11月)。他持有the University of Colorado的分子生物学学士学位，Stanford University School of Medicine的医学博士学位，以及the Harvard School of Public Health的公共卫生硕士学位。
- Alan Colowick, M.D. Dr. Colowick has served on Personalis, Inc. of Directors since May 2019. Dr. Colowick has served on the board of directors of Harpoon Therapeutics, Inc., a publicly traded clinical stage immunotherapy company, since March 2021. From May 2017 to January 2021 Dr. Colowick served as a Partner at Sofinnova Investment, Inc., a clinical stage life sciences venture capital firm. From February 2010 to April 2017 Dr. Colowick held various positions, including Executive Vice President, at Celgene Corporation, a pharmaceutical company. From February 2008 to January 2010 Dr. Colowick served as the Chief Executive Officer of Gloucester Pharmaceuticals Inc., an early stage cancer pharmaceutical company, until its acquisition by Celgene Corporation in January 2010. From October 2006 to February 2008 Dr. Colowick served as President, Oncology at Geron Corporation, an early stage pharmaceutical company. Earlier in his career, Dr. Colowick served in various capacities at Amgen Inc., a biopharmaceutical company. Dr. Colowick previously served on the boards of directors of Principia Biopharma, Inc., a publicly traded biopharmaceutical company, from February 2017 to September 2020 Achaogen, Inc., a publicly traded biopharmaceutical company, from August 2015 to August 2017 and Dimension Therapeutics, Inc., a publicly traded biopharmaceutical company, from August 2015 to November 2017. Dr. Colowick holds a B.S. in Molecular Biology from the University of Colorado, an M.D. from Stanford University School of Medicine, and an M.P.H. from the Harvard School of Public Health.
- Kenneth Ludlum
-
Kenneth Ludlum自2015年7月起担任Personalis, Inc.的董事。自2019年4月起，他担任IRIDEX Corporation(一家上市的医疗技术公司)的董事会成员。从2002年1月到2020年6月，他担任Natus Medical Inc.(上市的医疗设备和设备公司)的董事会成员。从2014年2月到2016年4月，他担任CareDx, Inc.(分子诊断公司)的首席财务官;在此之前，他担任其他上市公司的首席财务官。他持有Lehigh University的工商管理学士学位和Columbia Business School的工商管理硕士学位。
Kenneth Ludlum has served on Personalis, Inc. of Directors since July 2015. Mr. Ludlum has served on the board of directors of IRIDEX Corporation, a publicly traded medical technology company, since April 2019. From January 2002 to June 2020 Mr. Ludlum served on the board of directors of Natus Medical Inc., a publicly traded medical device and equipment company. From February 2014 to April 2016 Mr. Ludlum served as Chief Financial Officer at CareDx, Inc., a molecular diagnostics company, and prior to that Mr. Ludlum served as a Chief Financial Officer for other publicly traded companies. Mr. Ludlum holds a B.S. in Business Administration from Lehigh University and an M.B.A. from Columbia Business School. - Kenneth Ludlum自2015年7月起担任Personalis, Inc.的董事。自2019年4月起，他担任IRIDEX Corporation(一家上市的医疗技术公司)的董事会成员。从2002年1月到2020年6月，他担任Natus Medical Inc.(上市的医疗设备和设备公司)的董事会成员。从2014年2月到2016年4月，他担任CareDx, Inc.(分子诊断公司)的首席财务官;在此之前，他担任其他上市公司的首席财务官。他持有Lehigh University的工商管理学士学位和Columbia Business School的工商管理硕士学位。
- Kenneth Ludlum has served on Personalis, Inc. of Directors since July 2015. Mr. Ludlum has served on the board of directors of IRIDEX Corporation, a publicly traded medical technology company, since April 2019. From January 2002 to June 2020 Mr. Ludlum served on the board of directors of Natus Medical Inc., a publicly traded medical device and equipment company. From February 2014 to April 2016 Mr. Ludlum served as Chief Financial Officer at CareDx, Inc., a molecular diagnostics company, and prior to that Mr. Ludlum served as a Chief Financial Officer for other publicly traded companies. Mr. Ludlum holds a B.S. in Business Administration from Lehigh University and an M.B.A. from Columbia Business School.
- Woodrow A. Myers, Jr.
-
Woodrow A. Myers, Jr.，医学博士，自2021年3月起担任Personalis, Inc.的董事。从2007年5月到2018年12月，Myers博士担任Express Scripts Inc.（一家上市医疗保健公司）的董事会成员。从2018年1月到2019年2月，Myers博士担任亚利桑那州蓝十字蓝盾公司的首席医疗官和首席医疗保健策略师。自2015年12月以来，Myers博士担任Myers Ventures LLC（医疗咨询公司）的董事总经理。Myers博士持有Stanford University的生物学学士学位、Stanford Graduate School of Business的工商管理硕士学位和Harvard Medical School的医学博士学位。
Woodrow A. Myers, Jr., M.D. has served on Personalis, Inc. of Directors since March 2021. From May 2007 to December 2018 Dr. Myers served on the board of directors of Express Scripts Inc., a publicly traded health care company. From January 2018 to February 2019 Dr. Myers served as Chief Medical Officer and Chief Healthcare Strategist for Blue Cross Blue Shield of Arizona. Since December 2015 Dr. Myers has served as Managing Director of Myers Ventures LLC, a healthcare consulting company. Dr. Myers holds a B.S. in Biology from Stanford University, an M.B.A. from Stanford Graduate School of Business, and an M.D. from Harvard Medical School. - Woodrow A. Myers, Jr.，医学博士，自2021年3月起担任Personalis, Inc.的董事。从2007年5月到2018年12月，Myers博士担任Express Scripts Inc.（一家上市医疗保健公司）的董事会成员。从2018年1月到2019年2月，Myers博士担任亚利桑那州蓝十字蓝盾公司的首席医疗官和首席医疗保健策略师。自2015年12月以来，Myers博士担任Myers Ventures LLC（医疗咨询公司）的董事总经理。Myers博士持有Stanford University的生物学学士学位、Stanford Graduate School of Business的工商管理硕士学位和Harvard Medical School的医学博士学位。
- Woodrow A. Myers, Jr., M.D. has served on Personalis, Inc. of Directors since March 2021. From May 2007 to December 2018 Dr. Myers served on the board of directors of Express Scripts Inc., a publicly traded health care company. From January 2018 to February 2019 Dr. Myers served as Chief Medical Officer and Chief Healthcare Strategist for Blue Cross Blue Shield of Arizona. Since December 2015 Dr. Myers has served as Managing Director of Myers Ventures LLC, a healthcare consulting company. Dr. Myers holds a B.S. in Biology from Stanford University, an M.B.A. from Stanford Graduate School of Business, and an M.D. from Harvard Medical School.
- Karin Eastham
-
Karin Eastham，自2019年9月起担任Personalis, Inc.的董事。她于2018年9月被任命为Personalis, Inc.董事会成员。Eastham女士目前任职于几家生命科学公司的董事会。2009年3月以来担任Geron董事。Eastham女士也担任一家法兰克福证券交易所上市的生物技术公司MorphoSys AG，一家生命科学工具和试剂制造商Illumina，以及一家私营分子诊断公司Veracyte的董事。Eastham女士过去5年，2009年以来，也担任一家生物制药公司Trius Therapeutics的董事，直到它2013年被卖出；2005年以来，担任一家生物制药公司Amylin Pharmaceuticals的董事，直到它2012年被卖出；2008年以来，担任一家专业实验服务提供商Genoptix的董事，直到它2011年被卖出；2003年以来，担任一家生物制药公司Tercica的董事，直到它2008年被卖出；2005年以来，担任一家生物制药公司SGX Pharmaceuticals的董事，直到它2008年被卖出。2004年5月到2008年9月，她担任一家涉及基础生物医疗项目的非盈利公司伯纳姆医学研究所的执行副总裁，首席运营官和董事会成员。1999年到2004年，Eastham女士担任一家生物技术公司Diversa Corporation的金融高级副总裁，首席财务官和秘书长。她之前在一家计算化学公司CombiChem和一家生物制药公司Cytel Corporation担任相似的职位。1976年到1988年，Eastham女士也在一家生物制药公司Boehringer Mannheim Corporation担任几个职位，包括金融副总裁。Eastham女士拥有印第安纳大学的学士学位和MBA学位，她是一名注册会计师。
Karin Eastham, has served on Personalis, Inc. of Directors since September 2019. She was appointed to serve as a member of our board of directors in September 2018. Ms. Eastham currently serves on the boards of directors of several life sciences companies. Ms. Eastham has served on the board of directors of Geron Corporation since March 2009 Veracyte, Inc. since December 2012 and Personalis, Inc. since November 2019. Ms. Eastham served as a member of the board of directors of Illumina Inc. from August 2004 to May 2019 MorphoSys AG from May 2012 to May 2017 Amylin Pharmaceuticals, Inc. from September 2005 until its acquisition in August 2012 Genoptix, Inc. from July 2008 until its acquisition in March 2011 Tercica, Inc. from December 2003 until its acquisition in October 2008 and Trius Therapeutics, Inc. from February 2007 until its acquisition in September 2013. From May 2004 to September 2008 Ms. Eastham served as Executive Vice President and Chief Operating Officer, and as a member of the Board of Trustees, of the Burnham Institute for Medical Research now Sanford Burnham Prebys Medical Discovery Institute, a non-profit corporation engaged in biomedical research. From April 1999 to May 2004 Ms. Eastham served as Senior Vice President, Chief Financial Officer and Secretary of Diversa Corporation, a biotechnology company. Ms. Eastham previously held similar positions with CombiChem, Inc., a computational chemistry company, and Cytel Corporation, a biopharmaceutical company. Ms. Eastham also held several positions, including Vice President, Finance, at Boehringer Mannheim Diagnostics, from 1976 to 1988. Ms. Eastham received a B.S. in Accounting and an M.B.A. from Indiana University and is a Certified Public Accountant. - Karin Eastham，自2019年9月起担任Personalis, Inc.的董事。她于2018年9月被任命为Personalis, Inc.董事会成员。Eastham女士目前任职于几家生命科学公司的董事会。2009年3月以来担任Geron董事。Eastham女士也担任一家法兰克福证券交易所上市的生物技术公司MorphoSys AG，一家生命科学工具和试剂制造商Illumina，以及一家私营分子诊断公司Veracyte的董事。Eastham女士过去5年，2009年以来，也担任一家生物制药公司Trius Therapeutics的董事，直到它2013年被卖出；2005年以来，担任一家生物制药公司Amylin Pharmaceuticals的董事，直到它2012年被卖出；2008年以来，担任一家专业实验服务提供商Genoptix的董事，直到它2011年被卖出；2003年以来，担任一家生物制药公司Tercica的董事，直到它2008年被卖出；2005年以来，担任一家生物制药公司SGX Pharmaceuticals的董事，直到它2008年被卖出。2004年5月到2008年9月，她担任一家涉及基础生物医疗项目的非盈利公司伯纳姆医学研究所的执行副总裁，首席运营官和董事会成员。1999年到2004年，Eastham女士担任一家生物技术公司Diversa Corporation的金融高级副总裁，首席财务官和秘书长。她之前在一家计算化学公司CombiChem和一家生物制药公司Cytel Corporation担任相似的职位。1976年到1988年，Eastham女士也在一家生物制药公司Boehringer Mannheim Corporation担任几个职位，包括金融副总裁。Eastham女士拥有印第安纳大学的学士学位和MBA学位，她是一名注册会计师。
- Karin Eastham, has served on Personalis, Inc. of Directors since September 2019. She was appointed to serve as a member of our board of directors in September 2018. Ms. Eastham currently serves on the boards of directors of several life sciences companies. Ms. Eastham has served on the board of directors of Geron Corporation since March 2009 Veracyte, Inc. since December 2012 and Personalis, Inc. since November 2019. Ms. Eastham served as a member of the board of directors of Illumina Inc. from August 2004 to May 2019 MorphoSys AG from May 2012 to May 2017 Amylin Pharmaceuticals, Inc. from September 2005 until its acquisition in August 2012 Genoptix, Inc. from July 2008 until its acquisition in March 2011 Tercica, Inc. from December 2003 until its acquisition in October 2008 and Trius Therapeutics, Inc. from February 2007 until its acquisition in September 2013. From May 2004 to September 2008 Ms. Eastham served as Executive Vice President and Chief Operating Officer, and as a member of the Board of Trustees, of the Burnham Institute for Medical Research now Sanford Burnham Prebys Medical Discovery Institute, a non-profit corporation engaged in biomedical research. From April 1999 to May 2004 Ms. Eastham served as Senior Vice President, Chief Financial Officer and Secretary of Diversa Corporation, a biotechnology company. Ms. Eastham previously held similar positions with CombiChem, Inc., a computational chemistry company, and Cytel Corporation, a biopharmaceutical company. Ms. Eastham also held several positions, including Vice President, Finance, at Boehringer Mannheim Diagnostics, from 1976 to 1988. Ms. Eastham received a B.S. in Accounting and an M.B.A. from Indiana University and is a Certified Public Accountant.
- A. Blaine Bowman
-
A. Blaine Bowman， 自2007年1月起出任董事。曾任在纳斯达克上市的分析仪器制造商Dionex公司的董事长，总裁兼首席执行官。2002年从Dionex公司的总裁兼首席执行官职位退休， 2005年从董事会主席位置退休，但他仍然是Dionex公司的董事，直至2011年其出售给Thermo Fisher科技公司。他于1977年加入Dionex，并于1980年被任命为总裁兼首席执行官。加入戴安之前，他是管理咨询公司麦肯锡公司一位管理顾问和通信设备公司摩托罗拉半导体产品部的产品工程师。他还担任在纳斯达克上市可编程逻辑解决方案的供应商Altera公司，和一家私人持有的致力于通过使用nanoproteomics研究蛋白质的生命科学公司ProteinSimple的董事。自1985年到2007年其出售给MDS公司，他还担任在纳斯达克上市的为生命科学研究人员提供仪器和耗材供应商Molecular设备公司的前任董事。2006年直到2007年其被Illumina公司收购，担任Solexa公司的前董事。鲍曼先生在Brigham Young大学获得他的物理学学士学位，在斯坦福大学获得工商管理硕士学位。
A. Blaine Bowman has served on Personalis, Inc. of Directors since May 2019. Beginning in 2006 Mr. Bowman served on the board of directors of Solexa, Inc., a DNA sequencing company, until its sale to Illumina, Inc., a publicly traded biotechnology company in January 2007 after which Mr. Bowman continued to serve on the board of directors of Illumina, Inc. until May 2018. From March 1977 to August 2005 Mr. Bowman served in various roles at Dionex Corporation, a publicly traded manufacturer of analytical instruments, including Chairman of the board of directors, President, and Chief Executive Officer, and he served on the board of directors until its sale to Thermo Fisher Scientific Inc. in May 2011. From July 2012 to December 2015 Mr. Bowman served on the board of directors of Altera Corporation, a publicly traded programmable logic devices company. Mr. Bowman holds a B.S. in Physics from Brigham Young University and an M.B.A. from the Stanford Graduate School of Business. - A. Blaine Bowman， 自2007年1月起出任董事。曾任在纳斯达克上市的分析仪器制造商Dionex公司的董事长，总裁兼首席执行官。2002年从Dionex公司的总裁兼首席执行官职位退休， 2005年从董事会主席位置退休，但他仍然是Dionex公司的董事，直至2011年其出售给Thermo Fisher科技公司。他于1977年加入Dionex，并于1980年被任命为总裁兼首席执行官。加入戴安之前，他是管理咨询公司麦肯锡公司一位管理顾问和通信设备公司摩托罗拉半导体产品部的产品工程师。他还担任在纳斯达克上市可编程逻辑解决方案的供应商Altera公司，和一家私人持有的致力于通过使用nanoproteomics研究蛋白质的生命科学公司ProteinSimple的董事。自1985年到2007年其出售给MDS公司，他还担任在纳斯达克上市的为生命科学研究人员提供仪器和耗材供应商Molecular设备公司的前任董事。2006年直到2007年其被Illumina公司收购，担任Solexa公司的前董事。鲍曼先生在Brigham Young大学获得他的物理学学士学位，在斯坦福大学获得工商管理硕士学位。
- A. Blaine Bowman has served on Personalis, Inc. of Directors since May 2019. Beginning in 2006 Mr. Bowman served on the board of directors of Solexa, Inc., a DNA sequencing company, until its sale to Illumina, Inc., a publicly traded biotechnology company in January 2007 after which Mr. Bowman continued to serve on the board of directors of Illumina, Inc. until May 2018. From March 1977 to August 2005 Mr. Bowman served in various roles at Dionex Corporation, a publicly traded manufacturer of analytical instruments, including Chairman of the board of directors, President, and Chief Executive Officer, and he served on the board of directors until its sale to Thermo Fisher Scientific Inc. in May 2011. From July 2012 to December 2015 Mr. Bowman served on the board of directors of Altera Corporation, a publicly traded programmable logic devices company. Mr. Bowman holds a B.S. in Physics from Brigham Young University and an M.B.A. from the Stanford Graduate School of Business.
高管简历
中英对照 | 中文 | 英文- John West
John West，他是Personalis, Inc.的创始人之一，自2011年8月起担任Personalis, Inc.的首席执行官和董事。从2009年5月到2011年7月，他担任ViaCyte, Inc.(再生医学公司)的首席执行官。从2004年8月到2008年1月，他担任各种职务，包括从2004年8月到2005年3月担任Solexa, Ltd (DNA测序公司，后来成为Solexa, Inc.)的首席执行官，从2005年3月到2007年1月担任Solexa, Inc.的首席执行官。2007年1月至2008年1月担任Illumina公司(生物技术公司)的DNA测序高级副总裁，此前Solexa公司被Illumina公司收购。West先生的早期职业生涯包括与DNA测序自动化相关的职位。他持有麻省理工学院(Massachusetts Institute of Technology)的核工程学士学位和机械工程硕士学位，以及宾夕法尼亚大学(University of Pennsylvania)沃顿商学院(Wharton School)的工商管理硕士学位。
John West is one of Personalis, Inc. founders and has served as Chief Executive Officer and as a member of Personalis, Inc. of Directors since August 2011. From May 2009 to July 2011 Mr. West served as Chief Executive Officer of ViaCyte, Inc., a regenerative medicine company. From August 2004 to January 2008 Mr. West served in various roles, including Chief Executive Officer from August 2004 to March 2005 at Solexa, Ltd., a DNA sequencing company, which became Solexa, Inc., Chief Executive Officer from March 2005 to January 2007 at Solexa, Inc., and Senior Vice President of DNA Sequencing from January 2007 to January 2008 at Illumina, Inc., a biotechnology company, after the sale of Solexa, Inc. to Illumina, Inc. Mr. West's earlier career included positions related to DNA sequencing automation. Mr. West holds a B.S. in Nuclear Engineering and an M.S. in Mechanical Engineering from Massachusetts Institute of Technology and an M.B.A. from the Wharton School at the University of Pennsylvania.- John West，他是Personalis, Inc.的创始人之一，自2011年8月起担任Personalis, Inc.的首席执行官和董事。从2009年5月到2011年7月，他担任ViaCyte, Inc.(再生医学公司)的首席执行官。从2004年8月到2008年1月，他担任各种职务，包括从2004年8月到2005年3月担任Solexa, Ltd (DNA测序公司，后来成为Solexa, Inc.)的首席执行官，从2005年3月到2007年1月担任Solexa, Inc.的首席执行官。2007年1月至2008年1月担任Illumina公司(生物技术公司)的DNA测序高级副总裁，此前Solexa公司被Illumina公司收购。West先生的早期职业生涯包括与DNA测序自动化相关的职位。他持有麻省理工学院(Massachusetts Institute of Technology)的核工程学士学位和机械工程硕士学位，以及宾夕法尼亚大学(University of Pennsylvania)沃顿商学院(Wharton School)的工商管理硕士学位。
- John West is one of Personalis, Inc. founders and has served as Chief Executive Officer and as a member of Personalis, Inc. of Directors since August 2011. From May 2009 to July 2011 Mr. West served as Chief Executive Officer of ViaCyte, Inc., a regenerative medicine company. From August 2004 to January 2008 Mr. West served in various roles, including Chief Executive Officer from August 2004 to March 2005 at Solexa, Ltd., a DNA sequencing company, which became Solexa, Inc., Chief Executive Officer from March 2005 to January 2007 at Solexa, Inc., and Senior Vice President of DNA Sequencing from January 2007 to January 2008 at Illumina, Inc., a biotechnology company, after the sale of Solexa, Inc. to Illumina, Inc. Mr. West's earlier career included positions related to DNA sequencing automation. Mr. West holds a B.S. in Nuclear Engineering and an M.S. in Mechanical Engineering from Massachusetts Institute of Technology and an M.B.A. from the Wharton School at the University of Pennsylvania.
- Aaron Tachibana
Aaron Tachibana，自2010年3月，Aaron Tachibana先生成为Pericom的金融高级副总裁，首席财务官。在2013年10月3日报道Form 8-K之前，Tachibana先生通知本公司，他将辞去他在本公司的首席财务官职位，以便追求在其他的机会。他的辞职将在2013年11月4日生效。本公司感谢自此三年半期间Aaron为公司的专门服务和他的许多贡献。2008年8月至2010年2月，他担任Asyst Technologies, Inc. 的高级副总裁和首席财务官。2009年4月20日，Asyst提出在美国破产法11章下自愿申请救助，其日本子公司在日本公司重组发下签订有关自愿程序。2004年6月，他加入Asyst担任分部财务总监。2007年6月至2008年8月，Tachibana先生担任Asyst金融副总裁，首席会计员；2005年1月至2007年5月担任FP&A ，运作资金高级主管；2004年6月至2004年12月担任分部财务总监。2000年12月至2003年6月，Tachibana先生是网络解决方案供应商Allied Telesyn, Inc.的公司规划和发展副总裁。1999年11月至2000年10月，他担任软件应用程序和将内容传送到无线设备的供应商TapCast, Inc.的副总裁和首席财务官；1997年7月至1999年10月，他是光学记录和存储设备供应商TeraStor Corporation的副总裁和财务总监。此前，Tachibana 先生也担任Maxtor Corporation的财务职位并担任the General Electric Company财务管理计划的一个成员。Tachibana先生持有San Jose State University的工商管理学士学位。
Aaron Tachibana has served as Personalis, Inc. Chief Financial Officer since March 2019. From August 2015 to September 2018 Mr. Tachibana served as Chief Financial Officer at Lumentum Holdings Inc., a designer and manufacturer of optical and photonic products. From November 2013 to July 2015 Mr. Tachibana served as Vice President, Finance and Corporate Controller at JDS Uniphase Corp., subsequently renamed Viavi Solutions Inc., a network test, measurement, and assurance technology company. From March 2010 to October 2013 Mr. Tachibana served as Chief Financial Officer at Pericom Semiconductor Corp., a supplier of high-performance connectivity and timing solutions. Mr. Tachibana holds a B.S. in Business Administration and Finance from San Jose State University.- Aaron Tachibana，自2010年3月，Aaron Tachibana先生成为Pericom的金融高级副总裁，首席财务官。在2013年10月3日报道Form 8-K之前，Tachibana先生通知本公司，他将辞去他在本公司的首席财务官职位，以便追求在其他的机会。他的辞职将在2013年11月4日生效。本公司感谢自此三年半期间Aaron为公司的专门服务和他的许多贡献。2008年8月至2010年2月，他担任Asyst Technologies, Inc. 的高级副总裁和首席财务官。2009年4月20日，Asyst提出在美国破产法11章下自愿申请救助，其日本子公司在日本公司重组发下签订有关自愿程序。2004年6月，他加入Asyst担任分部财务总监。2007年6月至2008年8月，Tachibana先生担任Asyst金融副总裁，首席会计员；2005年1月至2007年5月担任FP&A ，运作资金高级主管；2004年6月至2004年12月担任分部财务总监。2000年12月至2003年6月，Tachibana先生是网络解决方案供应商Allied Telesyn, Inc.的公司规划和发展副总裁。1999年11月至2000年10月，他担任软件应用程序和将内容传送到无线设备的供应商TapCast, Inc.的副总裁和首席财务官；1997年7月至1999年10月，他是光学记录和存储设备供应商TeraStor Corporation的副总裁和财务总监。此前，Tachibana 先生也担任Maxtor Corporation的财务职位并担任the General Electric Company财务管理计划的一个成员。Tachibana先生持有San Jose State University的工商管理学士学位。
- Aaron Tachibana has served as Personalis, Inc. Chief Financial Officer since March 2019. From August 2015 to September 2018 Mr. Tachibana served as Chief Financial Officer at Lumentum Holdings Inc., a designer and manufacturer of optical and photonic products. From November 2013 to July 2015 Mr. Tachibana served as Vice President, Finance and Corporate Controller at JDS Uniphase Corp., subsequently renamed Viavi Solutions Inc., a network test, measurement, and assurance technology company. From March 2010 to October 2013 Mr. Tachibana served as Chief Financial Officer at Pericom Semiconductor Corp., a supplier of high-performance connectivity and timing solutions. Mr. Tachibana holds a B.S. in Business Administration and Finance from San Jose State University.
- Richard Chen
Richard Chen，他曾担任Personalis, Inc.的董事。2011年11月起担任首席科学官。自2011年9月起，他担任Stanford University School of Medicine的临床教员。1997年8月，他联合创立了基因数据软件公司——匠心系统公司。他持有Stanford University的计算机科学学士学位，Stanford University School of Medicine的医学信息学硕士学位，以及Stanford University School of Medicine的医学博士学位。
Richard Chen has served as Personalis, Inc. Chief Scientific Officer since November 2011. Since September 2011 Dr. Chen has served on the clinical faculty at Stanford University School of Medicine. In August 1997 Dr. Chen co-founded Ingenuity Systems, a genomic data software company. Dr. Chen holds a B.S. in Computer Science from Stanford University, an M.S. in Medical Informatics from Stanford University School of Medicine, and an M.D. from Stanford University School of Medicine.- Richard Chen，他曾担任Personalis, Inc.的董事。2011年11月起担任首席科学官。自2011年9月起，他担任Stanford University School of Medicine的临床教员。1997年8月，他联合创立了基因数据软件公司——匠心系统公司。他持有Stanford University的计算机科学学士学位，Stanford University School of Medicine的医学信息学硕士学位，以及Stanford University School of Medicine的医学博士学位。
- Richard Chen has served as Personalis, Inc. Chief Scientific Officer since November 2011. Since September 2011 Dr. Chen has served on the clinical faculty at Stanford University School of Medicine. In August 1997 Dr. Chen co-founded Ingenuity Systems, a genomic data software company. Dr. Chen holds a B.S. in Computer Science from Stanford University, an M.S. in Medical Informatics from Stanford University School of Medicine, and an M.D. from Stanford University School of Medicine.